 |
|
|
| |
Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
CD Spinner1, A Stoehr2, A Wong3, J de Wet4, J Zeggagh5, L Hocqueloux6, B van Welzen7, M Heinzkill8, S Sahali9, A Torres Cornejo10, H Ramroth11, R Haubrich12, D Thorpe13, CJ Kim14
1Technical University of Munich, University Hospital Rechts der Isar, Munich, Germany; 2IFI Studien und Projekte GmbH, Hamburg, Germany; 3University of Saskatchewan, Regina, Canada; 4Spectrum Health, Vancouver, Canada; 5Hopital Saint Louis, APHP, Paris, France; 6CHR d'Orleans, Orleans, France; 7University Medical Centre, Utrecht, Netherlands; 8Gilead Sciences GmbH, Munich, Germany; 9Gilead Sciences, Paris, France; 10Gilead Sciences Netherlands BV, Amsterdam, Netherlands; 11Gilead Sciences Ltd, London, UK; 12Gilead Sciences, Inc, Foster City, USA; 13Gilead Sciences Europe Ltd, London, UK; 14Gilead Sciences Canada, Inc, Mississauga, Canada
|
| |
|
|
|
|
|
